When Exercise Beats the Longevity Drug: A Closer Look at the RAPA-EX-01 Trial

Have you spent any time in the longevity corner of the internet? You've heard about rapamycin. Originally an immunosuppressant given to organ transplant patients, this drug has become the darling of the geroscience world because it extends lifespan in mice, slows certain markers of cellular aging in lab studies, and gets a lot of biohacker airtime as a potential anti-aging tool in humans. A new randomised, double-blind, placebo-controlled trial, RAPA-EX-01, just complicated the story. Specifically, it asked a question that had been nagging at researchers for a while. What happens when you stack weekly rapamycin on top of an exercise program in older adults? The answer, it turns out, is not what enthusiasts hoped.

Photo: Vitaly Gariev / Unsplash

What the research found

Researchers in New Zealand, working with collaborators at the University of Washington, randomised 40 sedentary adults aged 65 to 85 to either weekly oral sirolimus (rapamycin) at 6 milligrams or an identical placebo for 13 weeks. Both groups did the same home-based exercise program: chair stands and an exercycle, three times a week. The primary outcome was the change in 30-second chair-stand performance, a measure of lower-body power.

Both groups improved. That part isn't surprising; exercise works. What stood out was how the two groups compared. In the intention-to-treat analysis, the rapamycin group performed 2.13 fewer chair stands than the placebo group on average, a difference that didn't quite cross the conventional threshold for statistical significance (p = 0.089). Sensitivity analyses, the kind that look only at participants who completed the protocol as designed, told a sharper story. The per-protocol analysis showed a difference of 3.44 fewer reps in the rapamycin group (p = 0.007). Six-minute walk distance and grip strength also leaned slightly in the placebo group's favor, though those differences weren't statistically significant.

Adverse events tell their own part of the story. Both groups reported side effects at similar rates, with 17 of 20 participants in each arm reporting at least one event. The total burden of events was higher with rapamycin: 99 events versus 63 in the placebo arm. One serious adverse event, a case of pneumonia, was rated as possibly related to rapamycin. The authors concluded that once-weekly 6-mg sirolimus didn't enhance, and may have modestly attenuated, the short-term functional gains of a home exercise program in older adults.

This study was published in April 2026 in the Journal of Cachexia, Sarcopenia and Muscle.

Where this lands in the rapamycin literature

Rapamycin's reputation in the longevity space rests on a substantial preclinical evidence base. The drug inhibits a protein called mTOR, short for mechanistic target of rapamycin, which is one of the central control hubs the cell uses to decide whether to grow, repair, recycle, or rest. In animal studies, intermittent mTOR inhibition extends lifespan and improves multiple aging-related markers. A 2026 mechanistic paper in Aging Cell showed that low-dose rapamycin can reduce DNA damage signals and senescence markers in human immune cells, which lines up with the idea that the drug protects something meaningful at the cellular level.

The translation to humans, however, has been bumpy. A 2025 phase 1 trial of daily rapamycin in older adults with mild cognitive impairment found that the drug didn't even reach detectable levels in cerebrospinal fluid, while showing increases in some Alzheimer's-related biomarkers. None of this proves rapamycin is harmful in humans. It does mean we're still figuring out which doses, which schedules, and which populations might actually benefit, and which contexts might cost more than they give in ways that aren't obvious upfront.

The RAPA-EX-01 finding is specifically about the exercise-plus-drug combination. mTOR signaling is part of how muscle adapts to resistance training. Suppress mTOR at the wrong moment, and you might be blunting the very pathway your body needs to put on functional capacity. The "cycling hypothesis" the authors tested, alternating activation and inhibition of mTOR, didn't pay off in this short trial. Whether longer durations or different doses would change that picture, we don't yet know.

The naturopathic perspective

The longevity conversation often skips a step. People hear about a molecule that extends lifespan in mice, and the cultural pressure to optimize health pulls them toward off-label prescriptions, expensive subscriptions, or do-it-yourself stacking before the human evidence has been built out. RAPA-EX-01 is a useful corrective. The intervention that consistently outperformed in this trial, in both arms, was the exercise program. Chair stands and an exercycle, three times a week, for 13 weeks. The intervention that introduced more side effects, more events overall, and a possible attenuation of gains was the pharmaceutical layered on top.

That's a familiar pattern in naturopathic practice. The foundational interventions, the ones that work on the actual terrain of the body, often get under-credited in favor of whatever feels more sophisticated. Movement is one of those foundational pieces. So is sleep, protein adequacy, blood-sugar stability, micronutrient status, and stress regulation. None of them photograph well. All of them outperform their reputation.

That said, this trial is one carefully done early human study with a specific question and specific dose, and the rapamycin conversation continues beyond it. Future trials with different schedules may find populations and contexts where rapamycin earns its keep. For now, the safest reading is that adding a powerful systemic drug to an exercise program in healthy older adults is unlikely to be a free lunch, and the cost may be measurable.

How to apply this now

If you're working on healthy aging, the practical pieces here are neither glamorous nor new. Resistance training matters most. Two to three sessions a week of progressive overload, even with body weight or light dumbbells, builds the kind of lower-body power that protects function as you age. Pair that with adequate dietary protein distributed across meals, sleep that respects circadian rhythm, and consistent walking or low-intensity movement during the day. Those four things, done well, outperform almost any longevity supplement protocol.

If you're exploring a longevity-oriented medication, including rapamycin, that decision belongs in a substantive conversation with a clinician who knows your history, your medications, your infection risk, your goals, and the actual literature. Off-label prescribing for healthy aging is still experimental territory. There may be a meaningful benefit waiting for the right protocol, but the trade-offs are concrete, and trials like RAPA-EX-01 are how we figure out which is which.

References

1. Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial. J Cachexia Sarcopenia Muscle. 2026;17(2):e70274. PMID: 41985884. DOI. Original AANP digest link: https://pmc.ncbi.nlm.nih.gov/articles/PMC13082878/

2. Kell L, Jones EJ, Gharahdaghi N, et al. Rapamycin Exerts Its Geroprotective Effects in the Ageing Human Immune System by Enhancing Resilience Against DNA Damage. Aging Cell. 2026;25(2):e70364. PMID: 41524558. DOI.

3. Gonzales MM, Garbarino VR, Kautz TF, et al. Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial. Commun Med (Lond). 2025;5(1):189. PMID: 40394335. DOI.

A note before you go

Everything here is for educational purposes and is not a substitute for working with a provider who knows your history. Decisions about off-label prescription medications, including rapamycin or other longevity-focused agents, should always involve a licensed clinician who can weigh the full clinical picture with you.

---

If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.